World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
88126
World Ranking
2184
National Ranking
1233

Overview

A. John Iafrate is affiliated with Harvard University in the United States and has contributed extensively to medical research, with a particular focus on infectious diseases, molecular biology, oncology, and pulmonary medicine. Their work covers several domains, including SARS-CoV-2 and COVID-19 research as well as cancer genomics and diagnostics.

The scientist's research topics prominently include:

  • SARS-CoV-2 and COVID-19 Research
  • Cancer Genomics and Diagnostics
  • COVID-19 Clinical Research Studies
  • Lung Cancer Treatments and Mutations
  • SARS-CoV-2 detection and testing
  • Sarcoma Diagnosis and Treatment
  • Viral gastroenteritis research and epidemiology

Their main fields of study encompass Medicine and Biochemistry, Genetics and Molecular Biology. Subfields address Infectious Diseases, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, and Cancer Research.

Recent notable publications by A. John Iafrate include:

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, Cell
  • mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant, 2022, Cell
  • COVID-19-neutralizing antibodies predict disease severity and survival, 2020, Cell
  • Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, 2020, Science Immunology
  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, Cell

A. John Iafrate frequently collaborates with several co-authors, including:

  • Jochen K. Lennerz
  • Vivek Naranbhai
  • Julia Thierauf
  • Wilfredo F. García-Beltrán
  • Alejandro B. Balazs

The scientist's work appears in multiple publication venues, notably:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Cell

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Detection of large-scale variation in the human genome.

    A John Iafrate;Lars Feuk;Miguel N Rivera;Miguel N Rivera;Marc L Listewnik

  • Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

  • GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

    Shengdar Q Tsai;Zongli Zheng;Nhu T Nguyen;Matthew Liebers

  • Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

    Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

    Wilfredo F. Garcia-Beltran;Wilfredo F. Garcia-Beltran;Evan C. Lam;Kerri St. Denis;Adam D. Nitido

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

    Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  • Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma

    Itay Tirosh;Andrew S. Venteicher;Andrew S. Venteicher;Christine Hebert;Christine Hebert;Leah E. Escalante;Leah E. Escalante

  • Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

    Min Yu;Min Yu;Aditya Bardia;Nicola Aceto;Francesca Bersani

  • Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

    Andrew S. Venteicher;Andrew S. Venteicher;Itay Tirosh;Christine Hebert;Christine Hebert;Keren Yizhak;Keren Yizhak

  • Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

    Aaron N. Hata;Matthew J. Niederst;Hannah L. Archibald;Maria Gomez-Caraballo

Frequent Co-Authors

Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Alice T. Shaw
Alice T. Shaw Harvard University
Tracy T. Batchelor
Tracy T. Batchelor Brigham and Women's Hospital
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
David N. Louis
David N. Louis Harvard University
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Daniel A. Haber
Daniel A. Haber Harvard University
Todd R. Golub
Todd R. Golub Harvard University
Gad Getz
Gad Getz Broad Institute
Lecia V. Sequist
Lecia V. Sequist Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in studying Medicine in the USA but want to explore other healthcare careers, there are several flexible online degree paths to consider. For those who want to become registered nurses but are concerned about entrance exams, consider enrolling in a nursing school that does not require teas test. This can make starting your nursing education more accessible.

Individuals with an interest in the business side of healthcare may pursue an health administration degree. These online programs prepare students for leadership roles in hospitals, clinics, and other healthcare facilities without the commitment of medical school.

For those already holding an associate degree in nursing (ADN), advancing your career is possible through adn to fnp programs. These bridge programs offer a pathway to becoming a Family Nurse Practitioner, expanding both your knowledge and clinical opportunities.

If nutrition and wellness are your passions, consider exploring online nutrition degree programs. These allow students to study the science of healthy living from home, leading to careers in education, consulting, or health advocacy.

Best Scientists Citing A. John Iafrate

Trending Scientists